Cargando…

A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS)

PURPOSE: Antivascular endothelial growth factor agents are increasingly used in diabetic macular oedema (DME); however, there are few studies exploring their use in DME in real‐world settings. METHODS: POLARIS was a noninterventional, multicentre study to monitor 12‐month outcomes in patients starti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stefanickova, Jana, Cunha‐Vaz, Jose, Ulbig, Michael, Pearce, Ian, Fernández‐Vega Sanz, Alvaro, Theodossiadis, Panagiotis, Kodjikian, Laurent, Izmailov, Alexander, Muston, Dominic, Vassilev, Zdravko, Lamotte, Benedicte, Tückmantel, Claudia, Friedl, Sabine, Altemark, Andreas, Schwarz, Hans‐Jörg, Katz, Todd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585847/ https://www.ncbi.nlm.nih.gov/pubmed/29696809 http://dx.doi.org/10.1111/aos.13771

Ejemplares similares

Patient-reported outcomes in the RELIGHT clinical trial of ranibizumab in diabetic macular oedema
por: Chakravarthy, Usha, et al.
Publicado: (2019)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

The Norwegian Aurora Polaris Expedition 1902-1903
por: Birkeland, K R
Publicado: (2010)

Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
por: Wong, Yun, et al.
Publicado: (2016)

Reflections on an inflection: From virology to parasitology guided by POLARIS
por: Vaidya, Akhil B.
Publicado: (2018)

Characterization and Temperature Dependence of Arctic Micromonas polaris Viruses
por: Maat, Douwe S., et al.
Publicado: (2017)

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion
por: Thom, Howard HZ, et al.
Publicado: (2014)

Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment
por: Ziemssen, Focke, et al.
Publicado: (2017)

Technical assessment of the NDI Polaris Vega optical tracking system
por: Fattori, Giovanni, et al.
Publicado: (2021)

Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab
por: Talks, S. James, et al.
Publicado: (2019)

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
por: Prünte, Christian, et al.
Publicado: (2016)

Clinically meaningful visual improvements and predictors of early vision gains with ranibizumab for diabetic macular oedema
por: Morse, Lawrence, et al.
Publicado: (2019)

Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data
por: Sadda, Srinivas R., et al.
Publicado: (2019)

A Cilia Independent Role of Ift88/Polaris during Cell Migration
por: Boehlke, Christopher, et al.
Publicado: (2015)

The complete mitochondrial genome of Salix polaris, a specie in harsh arctic environment
por: Zhang, Li, et al.
Publicado: (2020)

Complete mitochondrial genome sequence and phylogenetic analysis of Lycodes polaris (Sabine, 1824)
por: Li, Hai, et al.
Publicado: (2019)

Cell composition inference and identification of layer-specific spatial transcriptional profiles with POLARIS
por: Chen, Jiawen, et al.
Publicado: (2023)

The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review
por: Ford, John A, et al.
Publicado: (2012)

Impact on visual acuity and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY)
por: Sakamoto, Taiji, et al.
Publicado: (2021)

Two-year visual and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY)
por: Sakamoto, Taiji, et al.
Publicado: (2022)

The PolariX-TDS Project: Bead-Pull Measurements and High-Power Test on the Prototype
por: Craievich, Paolo, et al.
Publicado: (2019)

Genome Sequence of Hymenobacter polaris RP-2-7(T), Isolated from Arctic Soil
por: Sundararaman, Aravind, et al.
Publicado: (2021)

Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab
por: Ebneter, Andreas, et al.
Publicado: (2016)

Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020)

Alterations in Retinal Vessel Diameters in Patients with Retinal Vein Occlusion before and after Treatment with Intravitreal Ranibizumab
por: Aissopou, Evaggelia, et al.
Publicado: (2023)

Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial
por: Mitchell, Paul, et al.
Publicado: (2012)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Konidaris, Vasileios E., et al.
Publicado: (2018)

Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema
por: Podkowinski, Dominika, et al.
Publicado: (2019)

Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Rodríguez-Fernández, Carmen Antía, et al.
Publicado: (2022)

Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis
por: Furuse, Junji, et al.
Publicado: (2017)

POLARIS: Polygenic LD‐adjusted risk score approach for set‐based analysis of GWAS data
por: Baker, Emily, et al.
Publicado: (2018)

Influence of Irradiance and Temperature on the Virus MpoV-45T Infecting the Arctic Picophytoplankter Micromonas polaris
por: Piedade, Gonçalo J., et al.
Publicado: (2018)

Comparative Evaluation of Combined Navigated Laser Photocoagulation and Intravitreal Ranibizumab in the Treatment of Diabetic Macular Edema
por: Liegl, Raffael, et al.
Publicado: (2014)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
por: Razavi, Sam, et al.
Publicado: (2021)

12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
por: Niedzwiecki, Mateusz, et al.
Publicado: (2021)

Gli2 and Gli3 Localize to Cilia and Require the Intraflagellar Transport Protein Polaris for Processing and Function
por: Haycraft, Courtney J, et al.
Publicado: (2005)

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Effects of UV Radiation on the Chlorophyte Micromonas polaris Host–Virus Interactions and MpoV-45T Virus Infectivity
por: Eich, Charlotte, et al.
Publicado: (2021)

The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema
por: Lang, Gabriele E., et al.
Publicado: (2017)

Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_le0cg3pknsv0okjspn9dpkfqcb